{"nctId":"NCT01792284","briefTitle":"A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus","startDateStruct":{"date":"2013-02"},"conditions":["Type 1 Diabetes Mellitus"],"count":212,"armGroups":[{"label":"LY2605541 Fixed Time Dosing","type":"EXPERIMENTAL","interventionNames":["Drug: LY2605541","Drug: Insulin Lispro"]},{"label":"LY2605541 Variable Time Dosing","type":"EXPERIMENTAL","interventionNames":["Drug: LY2605541","Drug: Insulin Lispro"]}],"interventions":[{"name":"LY2605541","otherNames":["Insulin Peglispro"]},{"name":"Insulin Lispro","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 1 diabetes mellitus for at least 1 year\n* Have an HbA1c value \\<9.0%\n* Have a body mass index (BMI) â‰¤35.0 kilogram per square meter (kg/m\\^2)\n* Currently using basal/ bolus insulin\n* Women of childbearing potential are not breastfeeding and must use methods to prevent pregnancy\n\nExclusion Criteria:\n\n* Have excessive insulin resistance\n* Are taking medications other than insulin for diabetes\n* High triglycerides\n* Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance due to neurologically disabling hypoglycemia as determined by the investigator) within 6 months prior to entry into the study\n* Have had 2 or more emergency room visits or hospitalizations due to poor glucose control (hyperglycemia or diabetic ketoacidosis) in the past 6 months\n* Have cardiac disease with functional status that is New York Heart Association (NYHA) Class III or IV (per NYHA Cardiac Disease Classification)\n* Have impaired renal function\n* Have impaired liver function\n* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, sickle cell anemia, or any other traits of hemoglobin abnormalities known to interfere with HbA1c measurement\n* Have cancer, recent cancer, or risk of cancer\n* Have a known hypersensitivity or allergy to any of the study insulins or their excipients\n* Have chronic systemic glucocorticoid users\n* Have clinically significant diabetic autonomic neuropathy\n* Have irregular sleep/wake cycle\n* Have been treated with a drug within the last 30 days that has not received regulatory approval at the time of study entry\n* Prior study participation\n* Are using or have used niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin A1c (HbA1c) at 12 Weeks","description":"HbA1c is a test that measures a person's average blood glucose level over the past 2 to 3 months. Least Squares (LS) means were calculated using a mixed model repeated measures (MMRM) analysis including the following fixed effects: treatment, period, sequence, baseline HbA1c (last nonmissing value at or before randomization), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.87","spread":"0.04"},{"groupId":"OG001","value":"6.93","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events","description":"Total hypoglycemic events (HE) include any event based on a blood glucose \\<=70 milligrams per deciliter (mg/dL) (3.9 millimoles per liter \\[mmol/L\\]), with or without signs/symptoms of hypoglycemia or an event associated with signs/symptoms of hypoglycemia but without a glucose measurement. Nocturnal HE include any total HE that occurred between bedtime and waking. Group Means are presented and were calculated from negative binomial regression models (number of episodes = treatment + period + treatment sequence + baseline HbA1c \\[\\<=8.0% or \\>8.0%\\], with log \\[exposure in days/30\\] as an offset variable). Group Mean (LS mean) is estimated by taking the inverse link function on individual participant covariates first and then averages over all participants.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.54","spread":"0.67"},{"groupId":"OG001","value":"10.37","spread":"0.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.52","spread":"0.13"},{"groupId":"OG001","value":"1.34","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Total and Nocturnal Hypoglycemic Events","description":"Total HE include any event based on a blood glucose \\<=70 mg/dL (3.9 mmol/L), with or without signs/symptoms of hypoglycemia or an event associated with signs/symptoms of hypoglycemia but without a glucose measurement. Nocturnal HE include any total HE that occurred between bedtime and waking. The percentage of participants was calculated by dividing the number of participants with hypoglycemic episodes by the total number of participants analyzed, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.2","spread":null},{"groupId":"OG001","value":"97.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.4","spread":null},{"groupId":"OG001","value":"80.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Blood Glucose (FBG) Measured by Self-Monitored Blood Glucose","description":"FBG was measured by self-monitored blood glucose (SMBG). LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline FBG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131.35","spread":"2.86"},{"groupId":"OG001","value":"139.65","spread":"2.87"}]}]}]},{"type":"SECONDARY","title":"Intra-Participant Variability of FBG at 12 Weeks","description":"FBG was measured by SMBG. Between-day glucose variability is measured by the standard deviation of FBG. LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline intra-participant variability in FBG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.97","spread":"1.73"},{"groupId":"OG001","value":"39.80","spread":"1.73"}]}]}]},{"type":"SECONDARY","title":"Fasting Serum Glucose (FSG) at 12 Weeks","description":"LS means for FSG (obtained from clinical laboratory tests) were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline FSG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121.51","spread":"4.27"},{"groupId":"OG001","value":"120.45","spread":"4.25"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization to 12 Weeks in 9-Point SMBG","description":"SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. SMBG measures were assessed at Weeks 0, 4, 8, and 12 within each Randomization Period. LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline SMBG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.77","spread":"3.79"},{"groupId":"OG001","value":"0.07","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"4.03"},{"groupId":"OG001","value":"8.13","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"3.55"},{"groupId":"OG001","value":"14.87","spread":"3.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.91","spread":"3.93"},{"groupId":"OG001","value":"5.40","spread":"3.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"3.81"},{"groupId":"OG001","value":"-1.34","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.49","spread":"4.06"},{"groupId":"OG001","value":"8.33","spread":"4.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.40","spread":"4.15"},{"groupId":"OG001","value":"5.36","spread":"4.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.05","spread":"3.55"},{"groupId":"OG001","value":"4.71","spread":"3.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.84","spread":"3.20"},{"groupId":"OG001","value":"-2.44","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Self-Monitored Blood Glucose (SMBG) at 12 Weeks","description":"SMBG measurements were taken at 9 time points: pre-morning meal, 2 hours post-morning meal, pre-midday meal, 2 hours post-midday meal, pre-evening meal, 2 hours post-evening meal, bedtime, at approximately 0300 hours, and the subsequent morning prior to the morning meal. SMBG measures were assessed at Weeks 0, 4, 8, and 12 within each Randomization Period. LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline SMBG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"133.21","spread":"3.79"},{"groupId":"OG001","value":"141.05","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"151.03","spread":"4.03"},{"groupId":"OG001","value":"160.41","spread":"4.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"122.96","spread":"3.55"},{"groupId":"OG001","value":"137.55","spread":"3.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147.05","spread":"3.93"},{"groupId":"OG001","value":"141.54","spread":"3.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"137.75","spread":"3.81"},{"groupId":"OG001","value":"134.43","spread":"3.84"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"150.37","spread":"4.06"},{"groupId":"OG001","value":"153.21","spread":"4.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"153.81","spread":"4.15"},{"groupId":"OG001","value":"150.77","spread":"4.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131.40","spread":"3.55"},{"groupId":"OG001","value":"143.16","spread":"3.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.16","spread":"3.20"},{"groupId":"OG001","value":"130.57","spread":"3.22"}]}]}]},{"type":"SECONDARY","title":"Intra-participant Variability in SMBG at 12 Weeks","description":"A summary of glucose variability (intra-participant variability) as measured by the average of between-day standard deviations of individual SMBG time points. LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline intra-participant variability in SMBG (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.82","spread":"1.30"},{"groupId":"OG001","value":"36.21","spread":"1.28"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization to 12 Weeks in Body Weight","description":"LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline body weight (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.19"},{"groupId":"OG001","value":"0.00","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Change From Day 1 of Lead-In Period to 36 Weeks in Body Weight","description":"LS means were calculated using MMRM analysis, including visit and baseline weight (last non-missing value at or before the beginning of Lead-in Period) as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"0.29"}]}]}]},{"type":"SECONDARY","title":"Change From Randomization to 12 Weeks in HbA1c","description":"LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline HbA1c (last nonmissing value at or before randomization), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"0.04"},{"groupId":"OG001","value":"0.18","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Participants With Treatment-Emergent Anti-LY2605541 Antibody Response","description":"The number of participants with a treatment emergent anti-LY2605541 antibody response (TEAR) is presented. Positive TEAR was defined as change from baseline to post-baseline in the anti-LY2605541 antibody level either from 1) undetectable to detectable or from 2) detectable to the value with at least 130% relative increase from baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null}]}]}]},{"type":"SECONDARY","title":"Basal, Bolus, and Total Insulin Doses at 12 Weeks","description":"LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline insulin dose (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.01"},{"groupId":"OG001","value":"0.51","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.01"},{"groupId":"OG001","value":"0.20","spread":"0.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":"0.01"},{"groupId":"OG001","value":"0.71","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Proportion of Bolus to Total Insulin Doses at 12 Weeks","description":"Proportion of bolus to total insulin dose is presented, where LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline proportion of bolus to total insulin dose (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.01"},{"groupId":"OG001","value":"0.28","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"0300-Hour Blood Glucose to Fasting Blood Glucose Excursion","description":"Excursion results were calculated by subtracting the 0300 hours glucose value from the next day pre-morning glucose value within a single SMBG profile. LS means were calculated using MMRM analysis including the following fixed effects: treatment, period, sequence, baseline 0300-hour to next day pre-breakfast excursion (last nonmissing value at or before randomization), baseline HbA1c (\\<=8.0% or \\>8.0%), week (defined from the start of each Randomization Period), and treatment-by-week interaction.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.41","spread":"3.64"},{"groupId":"OG001","value":"-15.24","spread":"3.70"}]}]}]},{"type":"SECONDARY","title":"Change From Day 1 of Lead-in to 36 Weeks in Triglycerides, Total Cholesterol, Low-Density Lipoprotein Cholesterol (LDL-C), and High-Density Lipoprotein Cholesterol (HDL-C)","description":"LS means were calculated using MMRM analysis including visit and baseline lipid level (last nonmissing value at or before the beginning of Lead-in) as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.44","spread":"3.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.75","spread":"1.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.45","spread":"1.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.70","spread":"0.82"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7.0% and â‰¤6.5% at 12 Weeks","description":"The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"54.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.1","spread":null},{"groupId":"OG001","value":"34.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":212},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Sinusitis","Sinus congestion","Influenza"]}}}